stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) EPS (diluted)
Insmed, Inc.'s EPS (diluted) for fiscal 2025 was −$6.42, compared with −$5.57 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$2.82. Over the past ten years it has ranged from −$6.42 (fiscal 2025) to −$2.02 (fiscal 2015) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 5 consecutive fiscal years. Insmed, Inc. ranks 367th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$6.42 | — |
| FY2024 | −$5.57 | — |
| FY2023 | −$5.34 | — |
| FY2022 | −$3.91 | — |
| FY2021 | −$3.88 | — |
| FY2020 | −$3.01 | — |
| FY2019 | −$3.01 | — |
| FY2018 | −$4.22 | — |
| FY2017 | −$2.89 | — |
| FY2016 | −$2.85 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.46 | — |
| Jun 2026 | −$0.06 | — |
| Mar 2026 | −$0.76 | — |
| Dec 2025 | −$1.54 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $19.26 |
| ASND Ascendis Pharma A/S compare | $12.89 |
| EXEL Exelixis, Inc. compare | $3.34 |
| INCY Incyte Corporation compare | $1.88 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| INSM Insmed, Inc. | −$2.82 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on INSM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement